Higher-Dose Liraglutide Creates New Options to Fight Obesity, but Payment Remains a Challenge
May 5th 2015Saxenda was approved in December 2014 to treat obesity, giving physicians another option for patients who are overweight and battling diabetes. Experts say payers need to take obesity as seriously as other conditions when making decisions about covering therapies.
Studies Are Showing SGLT2s Also Help Control Hypertension, Eliminate Some Side Effects
May 4th 2015Real-world studies of SGLT2 inhibitors show that this new class of drugs for type 2 diabetes has lowered A1C more than rivals. Patients lose more weight than with other oral therapies, and the benefit of controlling hypertension may make it possible for some patients to stop taking other drugs.